NCT01744691 - A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion | Biotech Hunter

Enrollment

145

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

June 30, 2014

Study Completion Date

April 30, 2016

Conditions

Chronic Lymphocytic Leukemia With 17p DeletionSmall Lymphocytic Lymphoma With 17p Deletion

Interventions

DRUG

Ibrutinib

All subjects will receive ibrutinib 420 mg (3 x 140-mg capsules) orally once daily.

Trial Locations (55)

55905

Rochester

Unknown

Phoenix

Duarte

Greenbrae

La Jolla

Stanford

Tampa

Chicago

Boston

Ann Arbor

St Louis

Hackensack

New Hyde Park

New York

Goldsboro

Columbus

Toldedo

Houston

Adelaide

Coburg

East Melbourne

Fremantle

Antwerp

Bruges

Brussels

Ghent

Kortrijk

Leuven

Roeselare

Edmonton

Cologne

Dresden

Heidelberg

Munich

Ulm

Auckland

Christchurch

Gothenburg

Lund

Stockholm

Ankara

Gaziantep

Istanbul

Izmir

Kayseri

Bournemouth

Glasgow

Leeds

Leicester

Liverpool

London

Manchester

Newcastle upon Tyne

Oxford

Plymouth